Linked Life Data

19207973

Source:http://linkedlifedata.com/resource/pubmed/id/19207973

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2009-2-11
pubmed:abstractText
The management of hepatitis B virus resistance to antivirals has evolved rapidly in recent years. The definition of resistance is now well established, with the importance of partial response and the improvement of assays to detect genotypic resistance and virological breakthrough. Data on phenotypic resistance have allowed to define the cross-resistance profile for the main resistant mutants, providing a rationale for treatment adaptation. Clinical studies have shown that an early treatment intervention in case of a virological breakthrough or a partial response with the addition of a second drug having a complementary cross-resistance profile allows one to maintain the majority of patients in clinical remission. The prevention of resistance should rely on the use of the most potent antivirals with a high genetic barrier to resistance as a first-line therapy. The future perspectives are to design strategies to hasten the HBsAg clearance, which should become a new treatment endpoint, to prevent drug resistance and to decrease the incidence of complications of chronic hepatitis B.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1478-3231
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
29 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
108-15
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Management and prevention of drug resistance in chronic hepatitis B.
pubmed:affiliation
INSERM, U871, Lyon, France. fabien.zoulim@inserm.fr
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't